Based on the key indicators related to Neurosense Therapeutics' liquidity, profitability, solvency, and operating efficiency, Neurosense Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, Neurosense Therapeutics' Cash is very stable compared to the past year. As of the 31st of January 2025, Non Currrent Assets Other is likely to grow to about 23.4 K, though Total Stockholder Equity is likely to grow to (1.6 M). Key indicators impacting Neurosense Therapeutics' financial strength include:
The essential information of the day-to-day investment outlook for Neurosense Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Neurosense Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Neurosense Therapeutics.
Neurosense Therapeutics competes with Quoin Pharmaceuticals, Revelation Biosciences, Virax Biolabs, Nutriband, and Longeveron LLC. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. Neurosense Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 11 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Neurosense Therapeutics's current stock value. Our valuation model uses many indicators to compare Neurosense Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Neurosense Therapeutics competition to find correlations between indicators driving Neurosense Therapeutics's intrinsic value. More Info.
Neurosense Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Neurosense Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Neurosense Therapeutics' earnings, one of the primary drivers of an investment's value.
Neurosense Therapeutics Systematic Risk
Neurosense Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Neurosense Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Neurosense Therapeutics correlated with the market. If Beta is less than 0 Neurosense Therapeutics generally moves in the opposite direction as compared to the market. If Neurosense Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Neurosense Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Neurosense Therapeutics is generally in the same direction as the market. If Beta > 1 Neurosense Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Neurosense Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Neurosense Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Neurosense Therapeutics growth as a starting point in their analysis.
Neurosense Therapeutics January 31, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Neurosense Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Neurosense Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Neurosense Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Neurosense Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Neurosense Therapeutics's daily price indicators and compare them against related drivers.
When determining whether Neurosense Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurosense Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurosense Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurosense Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.76)
Return On Assets
(1.51)
Return On Equity
(4.95)
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.